Skip to main content

Staphylococcus Aureus Bacteremia clinical trials at UC Davis
1 research study open to eligible people

  • A Study of the Safety and Efficiency of Experimental CF-301 for Staphylococcus aureus Bloodstream Infections (Bacteremia)

    “If you have a Staphylococcus aureus infection in your blood or heart, you may qualify to receive this investigational drug.”

    open to eligible people ages 18 years and up

    The purpose of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetics (PK) of CF-301 in addition to background standard of care (SOC) antibacterial therapy for the treatment of Staphylococcus aureus (S. aureus) bloodstream infections (bacteremia), including endocarditis in adults. Patients will be randomized to receive a single intravenous dose of CF-301 or placebo in addition to SOC antibacterial therapy. Patients will be prescribed standard of care antibiotics selected by the investigators based on their professional experience, practice guidelines and local antibiotic susceptibility information for the treatment of S. aureus bacteremia. CF-301 is a lysin and member of a new class of targeted protein-based antimicrobials that has demonstrated activity against S. aureus in laboratory (in vitro) and animal studies, alone and in addition to conventional antibiotics.

    Sacramento, California and other locations

Last updated: